Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.075
-0.005 (-0.46%)
At close: May 12, 2025, 4:00 PM
1.070
-0.005 (-0.47%)
After-hours: May 12, 2025, 5:17 PM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $174.00K in the quarter ending February 28, 2025, with 20.00% growth. This brings the company's revenue in the last twelve months to $525.92K, up 29.95% year-over-year. In the fiscal year ending August 31, 2024, Lexaria Bioscience had annual revenue of $464.28K with 105.24% growth.
Revenue (ttm)
$525.92K
Revenue Growth
+29.95%
P/S Ratio
32.72
Revenue / Employee
$75,132
Employees
7
Market Cap
20.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
| Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
LEXX News
- 14 hours ago - Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - Accesswire
- 14 hours ago - Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - TheNewswire
- 14 days ago - Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Accesswire
- 17 days ago - Lexaria Announces $2 Million Registered Direct Offering of Common Stock - Accesswire
- 19 days ago - Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology - Accesswire
- 5 weeks ago - Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - Accesswire
- 5 weeks ago - Lexaria's Human GLP-1 Study #5 Begins Dosing - Accesswire
- 7 weeks ago - Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound - TheNewswire